Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 5Phase 1/2 5Phase NA 3Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 124Other hematologic neoplasm 98Lymphoid 97Thoracic 96Genitourinary 93Other solid neoplasm 78CNS 66Breast 60Head & Neck 50Gynecologic 49Tumor-Agnostic 47Sarcoma 45Plasma cell 41Dermatologic 36Myeloid 30Endocrine 10Classical hematology 3NET 2Other 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 2peposertib 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Specimen Handling 1Single Photon Emission Computed Tomography Computed Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NET × 30 days × Clear all
NCT06122610 2026-05-15

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 1 Recruiting
10 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04750954 2026-05-13

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡